TriangleLiposomal irinotecan (NCT05854498)
Liposomal irinotecan trial for Metastatic Colorectal Cancer (NCT05854498). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic or unresectable, mismatch-repair-proficient colorectal cancer after fluorouracil, oxaliplatin and irinotecan. RAS-wild-type tumors require prior EGFR therapy and HER2 therapy if HER2-positive. BRAF-V600 tumors and prior TAS102 are excluded.
The idea: combine intravenous liposomal irinotecan and bevacizumab with oral TAS102. Chemotherapy disrupts DNA; bevacizumab blocks blood-vessel growth signals. Researchers measure time until progression or death and monitor responses and side effects.
This phase 2 study plans 50 patients. Dustin Deming leads it at the University of Wisconsin Carbone Cancer Center in Madison, the single recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.